Sage halts trials in Parkinson’s after drug fails to show benefit

5d ago, source:

The Cambridge company's experimental drug was being evaluated in a Phase 2 study in people with mild cognitive impairment in ...

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge

5d ago, source:

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow ...

Sage Therapeutics, Inc. (SAGE)

3d ago, source: Yahoo Finance

Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s ...

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

on MSN ago, source:

Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor ...

Sage Therapeutics Inc (SAGE): A Technical Analysis

6d ago, source: newsheater

Based on Sage Therapeutics Inc (SAGE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -104.66. The debt to equity ratio ...

Sage Therapeutics' Dalzanemdor Phase 2 Study Fails To Meet Primary Endpoint

5d ago, source:

Sage Therapeutics, Inc. (SAGE) announced that drug candidate Dalzanemdor, which is also known as SAGE-718, did not meet ...

Sage drops after mid-stage setback for Parkinson’s disease candidate

on MSN ago, source:

Sage Therapeutics (SAGE) stock plummeted after the company's Phase 2 trial for Parkinson’s disease candidate dalzanemdor ...

Sage Therapeutics Inc (SAGE) Stock: A Closer Look at the Moving Averages

10d ago, source: newsheater

Barrett Elizabeth, the Director of Sage Therapeutics Inc, purchase 1,000 shares at $50.50 during a trade that took place back on May 09 ’23, which means that Barrett Elizabeth is holding 1,000 shares ...

Sage Therapeutics Inc

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...